Ceretas Enrols First Patient In Phase 2 Alzheimer’s Trial
CTS: $0.900 +4.65% · MC: $67M
Ceretas has enrolled the first patient in its Phase 2 CERE-CALM trial, testing focused ultrasound as a treatment for behavioural symptoms in people with Alzheimer’s disease. The fully funded study is targeting at least 60 participants, with recruitment underway in Sydney and completion anticipated in the first half of 2028. It follows a 12-patient Phase 1 study that reported favourable safety and tolerability, alongside preliminary signs of symptom improvement.

Comments